November 17, 2026, 12pm-1pm ET
From the lab to the community: Familial Alzheimer’s disease in Jalisco, Mexico
Speakers: Dr. Angélica Zuno Reyes and Frida Rosales Leycegui
Autosomal dominant Alzheimer’s disease (ADAD) is a rare, inherited form of early- onset Alzheimer’s disease (AD) caused by nearly fully penetrant mutations, affecting families for generations. Because carriers of a causal mutation are born with a genetic alteration that virtually guarantees the onset of symptoms, often at a predictable age, ADAD offers a unique opportunity to study the disease before it manifests and throughout its stages, and to design preventive interventions for AD and related dementias. In Jalisco, Mexico, two large ADAD populations have been identified, carrying the PSEN1A431E (“Jalisco mutation”) or the APPV717I mutation.
This talk presents the work of a binational, multidisciplinary team at the Universidad de Guadalajara and the University of Southern California. Through an ongoing research protocol, the team has reconstructed historical pedigrees and conducted longitudinal functional, clinical, and cognitive assessments, as well as biosample collection, among other activities. Beyond the laboratory, we describe how community meetings and events, the development and implementation of genetic counseling programs, and social work and caregiving support have sustained long-term participant adherence, and how participants have become active partners in the research. Finally, we discuss future directions in neuroimaging, biomarkers, and clinical trials, and the role of community engagement in making ADAD research accessible and useful to the families it serves.
Please note that registration is required to attend. Click here to register.
December 15, 2026, 12pm-1pm ET
Genetic, pathologic and hormonal contributions to psychosis in Alzheimer’s disease
Speaker: Corinne Fischer
This presentation will examine putative mechanisms underlying psychosis in Alzheimer’s disease and how sex, APOE4 status and brain pathology may play a role. Specifically, we will examine how APOE4 status interacts with sex and pathology to determine psychotic phenotypes and how this knowledge may inform treatment. We will also examine the protective role of estrogen therapy in Alzheimer’s disease-related psychosis.
Please note that registration is required to attend. Click here to register.
Past webinars
What are you looking for?
Modest dietary carbohydrate restriction to sustain healthy cognitive aging
October 8, 2024
Sex and Gender research in CCNA: A sampling of current projects and future directions
April 23, 2024
Why sensory-cognitive research in aging and dementia requires a multi-disciplinary approach
April 9, 2024
Diversity in dementia research: Ethics and imperatives
March 12, 2024
Feasibility of delivering physical and cognitive interventions with older adults remotely in their own homes in New Brunswick – SYNERGIC@HOME
February 20, 2024
Is frailty a modifiable risk for dementia?
February 13, 2024
The journey to self-determination in Indigenous dementia research in Canada
January 30, 2024
“Yes, it’s possible!”: Engaging people with lived experience in national meetings
January 23, 2024
Issues in dementia care for rural populations
January 16, 2024
Immediate impacts of the COVID-19 pandemic on healthcare service use and experiences among persons living with dementia and their caregivers: a mixed methods study in four provinces
December 12, 2023
Profiling brain changes associated with apathy across neurodegenerative disorders
November 28, 2023
Advancing the field of driving and dementia
November 14, 2023






